Dose escalation study to assess PK, safety and tolerability of INC280 when taken with food in patients with cMET dysregulated advanced solid tumors.

Inclusion Criteria:

• cMET dysregulated advanced solid tumor
• At least one measurable lesion as defined by RECIST 1.1
• Recovered from all toxicities related to prior anti-cancer therapies to grade ≤ 1
• Adequate organ function
• ECOG performance status (PS) ≤ 1

Exclusion Criteria:

• Prior treatment with crizotinib or any other cMET or HGF inhibitor
• Known hypersensitivity to any of the excipients of INC280
• Symptomatic central nervous system (CNS) metastases who are neurologically unstable
• Presence or history of a malignant disease other than the study related cancer
• Clinically significant, uncontrolled heart diseases
• Thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting INC280 or patients who have not recovered from radiotherapy-related toxicities
• Major surgery within 4 weeks prior to starting INC280
• Impairment of GI function
• Patients receiving unstable or increasing doses of corticosteroids
• Patients receiving treatment with any enzyme-inducing anticonvulsant
• Pregnant or nursing (lactating) women Other protocol-related inclusion/exclusion criteria may apply